The P/E ratio is a critical metric for evaluating stock value, and Novo Nordisk's higher-than-average P/E ratio could lead to varied investor interpretations. While it may reflect optimism about the company's future earnings, it could also lead to concerns about overvaluation. The short-term impact on the stock price is uncertain, as it depends on market perception and subsequent investor actions.